Christopher Paul German - 20 Mar 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Corporate Controller & CAO
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German
Issuer symbol
RYTM
Transactions as of
20 Mar 2025
Net transactions value
-$18,655
Form type
4
Filing time
24 Mar 2025, 17:47:56 UTC
Previous filing
19 Feb 2025
Next filing
12 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +1,163 +56% 3,233 20 Mar 2025 Direct F1
transaction RYTM Common Stock Sale $18,655 -344 -11% $54.23 2,889 21 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -1,163 -33% $0.000000 2,324 20 Mar 2025 Common Stock 1,163 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in this Form 4 was effected pursuant to non-Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units have vested or will vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 20, 2026 and March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.